

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Previously Presented) A pharmaceutical composition for the treatment of a disease related to gastric hyperacidity, said composition comprising tenatoprazole and one or more histamine H<sub>2</sub>-receptor antagonists.
2. (Previously Presented) The composition according to claim 1, wherein the histamine H<sub>2</sub>-receptor antagonist is selected from the group consisting of cimetidine, ranitidine, famotidine and nizatidine.
3. (Previously Presented) The composition according to claim 1, wherein the weight ratio between tenatoprazole and the histamine H<sub>2</sub>-receptor antagonist is between 1:30 and 1:2.
4. (Previously Presented) The composition according to claim 1, wherein said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H<sub>2</sub>-receptor antagonist.
5. (Original) The composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.
6. (Previously Presented) The composition according to claim 1, wherein said composition is in a form for oral or parenteral administration.
7. (Cancelled)
8. (Cancelled)

9. (Previously Presented) The composition according to claim 2, wherein the weight ratio between tenatoprazole and the histamine H<sub>2</sub>-receptor antagonist is between 2:30 and 1:2.

10. (Previously Presented) The composition according to claim 2, wherein said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H<sub>2</sub>-receptor antagonist.

11. (Previously Presented) The composition according to claim 3, wherein said composition comprises between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H<sub>2</sub>-receptor antagonist.

12. (Previously Presented) The composition according to claim 2, wherein said composition is in a form for oral or parenteral administration.

13. (Previously Presented) The composition according to claim 3, wherein said composition is in a form for oral or parenteral administration.

14. (Previously Presented) The composition according to claim 4, wherein said composition is in a form for oral or parenteral administration.

15. (Previously Presented) The composition according to claim 5, wherein said composition is in a form for oral or parenteral administration.

16. (Previously Presented) A medicinal product useful for the treatment of a disease related to gastric hyperacidity, said product comprising tenatoprazole and at least one histamine H<sub>2</sub>-receptor antagonist.

17. (Previously Presented) A method of treating a disease related to gastric hyperacidity, said method comprising administering a medical product comprising tenatoprazole and at least one histamine H<sub>2</sub>-receptor antagonist.

18. (Previously Presented) The method of claim 17, wherein the disease related to gastric hyperacidity is gastric and duodenal ulcers and symptoms and lesions related to gastroesophageal reflux.

19. (Previously Presented) The composition according to claim 1, wherein the histamine H<sub>2</sub>-receptor antagonist is ranitidine.

20. (Previously Presented) The medicinal product of claim 16, wherein the histamine H<sub>2</sub>-receptor antagonist is ranitidine.

21. (Previously Presented) The method of claim 17, wherein the histamine H<sub>2</sub>-receptor antagonist is ranitidine.